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for PET/CT evaluation of HER2-expressing breast cancer tumours. These effective doses are somewhat higher than earlier published values for other 68 Ga-labelled tracers, for example 0.021 ± 0.003 mSv/MBq for 68 Ga-DOTATATE and 68 Ga-DOTATOC, mainly due to higher uptake in liver and kidney.
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INTRODUCTION
For women, breast cancer is currently the most common cancer. Human epidermal growth factor receptor 2 (HER2) is overexpressed in about one out of six cases (1) (2) (3) at initial diagnosis and is associated with poor survival (1, 3) . Treatments targeted to HER2, such as with the anti-HER2 antibody trastuzumab, have considerably improved the overall survival (1, 3, 4) . Today, assessment of HER2 status is based on tumor biopsies. However, HER2 expression can vary between the primary tumor and metastases in up to 40% of cases (2, 5, 6 ) and metastatic HER2 expression can change over time, which could necessitate a change of therapy (7, 8) . Follow-up using biopsies cannot always be performed due to practical reasons or patient discomfort.
Molecular imaging using single photon emission computed tomography (SPECT) and positron emission tomography (PET) might be a noninvasive, whole body based, way to evaluate the HER2 expression quantitatively. One such approach is the use of trastuzumab labeled with 111 In (t1/2 2.8 days) (9) or 89 Zr (t1/2 3.3 days) (10) for use with SPECT and PET, respectively, but the slow kinetics of antibodies require imaging several days after administration. One promising way of fast, safe and accurate imaging that specifically binds to a site on the receptor not occupied by current targeting therapeutic drugs (11) (12) (13) is to use the Affibody molecule ABY-025. ABY-025 labelled with 111 In used with SPECT has shown promising clinical results (14) which might be further improved today when semi-quantitative standardized uptake value (SUV) SPECT becomes available. The use of PET and ABY-025 labelled with 68 Ga (t1/2 68 min) has the potential to provide higher sensitivity, higher resolution images with lower absorbed and effective dose. The use of a short-lived positron emitter, combined with the higher sensitivity of PET and the much faster kinetics of ABY-025 compared to trastuzumab, will allow for imaging of the tumors within hours after injection instead of days, improving patient comfort and logistics. Tumor to background ratio, and hence detectability of tumors may be dependent on the total amount of peptide injected, since the number of occupation sites might be much higher in tumor sites. Hence the target receptors in normal organs can be saturated while the receptors in tumors are not. A preclinical study has previously indicated that it is possible to discriminate between low and high HER2-expression using Affibody molecules with low specific radioactivity (15) . Such discrimination has also been indicated in a clinical (14) and a preclinical study (16) considering the fast clearance of radioactivity from low HER2-expressing tumors.
68 Ga-ABY-025 and PET has, in a recent study, shown to be able to discriminate HER2-positive metastases, with SUV correlating well with HER2-expression (17) . In this study, two different amounts of peptides were administered, with the higher peptide dose giving the best results in terms of detectability and discrimination. The aim of the present work was to measure biodistribution and estimate radiation dosimetry of 68 Ga-ABY-025 in a single group of patients injected with two different peptide doses, but approximately the same amount of radioactivity, using dynamic and serial whole-body PET/CT.
MATERIALS & METHODS

Patients
Eight female patients diagnosed with metastatic breast cancer were included in the present work.
The study was an academically sponsored clinical trial (trial identifiers EudraCT 2012-005228-14
and NCT01858116), approved by the Regional Board of Medical Ethics and the Swedish Medical Products Agency. All patients signed an informed consent prior to inclusion in the study.
Radiochemistry
Good manufacturing practice compliant production of 68 Ga-ABY-025 (18) was conducted using a fractionation method (19) . 68 Ga was obtained from a 68 Ge/ all appropriate corrections and a 5.4 mm Gaussian post-filter. Venous blood samples were drawn after each whole body scan for measurement of whole blood radioactivity concentrations.
Patients were allowed to urinate between the dynamic scan and each consecutive whole body scan. Urine was collected, weighted, and radioactivity concentration was measured. Accurate cross-calibration between PET/CT, dose calibrator and well counters used to measure blood and urine activity was verified on a monthly basis and was always within 3%. The scan procedure was repeated one week later using 241 ± 49 (range, 159-297) MBq of HD 68 Ga-ABY-025.
Volumes of interest
Volumes of interest (VOI) were drawn in the whole-body images and in the last time frame of the dynamic image series over subsets of all clearly identifiable source organs liver, kidneys, spleen, and upper large intestine. VOIs drawn in the last frame of the dynamic scans were transferred to all earlier time frames. In addition, 70% isocontour regions of interest (ROIs) were drawn over 10 planes in first-pass images of the descending aorta and combined to a VOI, and transferred to all later dynamic time frames. Activity concentration and SUV normalized to body mass and injected amount of radioactivity were determined using the mean activity concentration in the VOIs. From these data time-activity curves (TACs) for these organs were computed. A wholeblood TAC was computed by combining the descending aorta TAC based on the dynamic scan with venous blood sample data taken after each whole-body scan.
Absorbed dose calculations
As in peptide receptor radionuclide therapy with 177 Lu-octreotate (20) red marrow radioactivity concentration was assumed to be equal to blood radioactivity concentration. Total organ activity was calculated by multiplication of the radioactivity concentrations with the organ weights of the adult reference female phantom (21) scaled by the total patient weight. Urinary bladder content was estimated based on linear interpolation between decay-corrected measured amounts of excreted radioactivity, assuming complete voiding. After the last scan, a 4 h voiding interval with filling rates equivalent to those prior to the last measured urine sample was assumed. Timeintegrated activity curves of the organ (TACs) were calculated by trapezoidal integration until the last scan, followed by a single-exponential fit to the last three data points extrapolated to infinity. 
Statistical analysis
Differences between residence times and absorbed doses for both peptide masses were assessed using a Wilcoxon signed-rank test included in the GraphPad Prism (version 6.02) software. Figure 1 shows typical whole-body images of a single patient for both peptide masses with clear reduction of hepatic radioactivity uptake for the HD. Figure 2 shows the biodistribution, in terms of SUV and percentage of injected activity per organ, for LD and HD. Of the major organs, the highest SUV at 60-240 min after injection was observed in the kidney, followed by liver. Figure 3 shows a direct comparison of the SUV in kidney and liver for LD versus HD. Initial uptake in the liver was higher for LD whilst clearance appeared similar for LD and HD, resulting in a higher residence time (p<0.05). For the kidney, a smaller difference in the same direction was found, whereas blood clearance was faster for LD. Residence times, as shown in Table 1 , considering mean data from the eight patients, where highest for liver, followed by the kidneys.
RESULTS
Absorbed dose estimates are shown in Table 2 . The highest absorbed organ doses were seen in kidney and liver. Absorbed doses to kidney, liver, gallbladder wall and total body were significantly higher for LD whereas red marrow absorbed dose was significantly higher for HD (Wilcoxon test, p<0.05), although mean absolute differences were very small for gallbladder wall (1%), total body (2%), and red marrow (2%).
DISCUSSION
To our knowledge, the present work is the first study of the radiation dosimetry of 68 Ga-ABY-025. Radiation absorbed doses were estimated using a protocol combining dynamic PET and serial whole-body PET scans in eight evaluable patients. An effective dose of 3.0 mSv and 2.8 mSv for LD and HD, respectively, will be achieved for a 100 MBq administration, which may be sufficient for clinical use. 68 Ga-ABY-025 should also be seen in the perspective that diagnostic CT-scans of the thorax and abdomen will give comparable or higher effective doses. In addition, many patients will undergo radiation treatment, leading to much higher radiation doses.
The use of a combined dynamic -whole body protocol allows for detailed assessment of the TACs of pre-defined risk organs, while improving patient comfort by allowing patients to leave the scanner between subsequent whole-body scans. The use of a 45 min dynamic scan has the disadvantage of not being able to follow other risk organs during this time. However, based on earlier studies with this compound (14) it was well known that the main source and risk organs were the liver and the kidneys. Since both of these can be imaged in one bed position the advantage of being able to image these organs over 45 min exceeded the disadvantage of not being able to image other risk organs during this time.
Absorbed doses in kidneys and liver were slightly higher for LD than for HD, and the same was observed for the effective dose. The differences in effective dose were minor even within individual patients. The organ receiving the highest absorbed radiation dose was the kidney followed by the liver. The absorbed dose to these organs, after a 100 MBq administration, will be approximately 40 mGy and 15 mGy for for kidney and liver, respectively, which is less than the maximum allowed absorbed dose of 50 mGy to a single organ in an healthy adult research subject (25).
Since the scan protocol covered the major part of the radioactive decay of 68 Ga, the remainder of the decay after the last scan amounts to at most a small percentage of the total number of disintegrations in each organ. Therefore, the uncertainty in extrapolation after the 4 h whole-body scan only has minor effects on the total estimate of the time-integrated activity.
The patients included in the present work all had breast cancer tumours and metastases with varying degree of HER2 expression, which is not accounted for in Olinda/EXM 1.1 calculations to assess radiation dosimetry. However, the tumour burden was limited, and since the major part of the absorbed dose to adrenal glands, kidneys and healthy liver tissue is due to locally absorbed beta radiation, taking into account cross-dose from tumours to healthy tissues would have resulted in negligible changes in organ doses.
CONCLUSION
The effective dose for a typical 200 MBq administration of 68 Ga-ABY-025 was found to be 6.0 mSv for LD (78±8 µg) and 5.6 mSv for HD (427±19 µg) of 68 Ga-ABY-025. The absorbed doses to kidneys and liver were lower for the HD than LD. Assuming that the tumour uptake was unaffected by peptide dose, these results suggest higher tumour to background contrast for HD.
Therefore, in terms of biodistribution and dosimetry, HD is preferred in the diagnosis and pretreatment HER2-status evaluation of breast cancer patients.
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